Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Onconova Therapeutics, Inc."
Count: 32
Selected: 0
| NCT ID | Title |
|---|
| NCT05705505 | Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer | ||
| NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | ||
| NCT02562443 | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | ||
| NCT02168725 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | ||
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | ||
| NCT01904682 | Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs | ||
| NCT02075034 | Three Dosing Schedules of Oral Rigosertib in MDS Patients | ||
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | ||
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | ||
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | ||
| NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | ||
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | ||
| NCT01584531 | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | ||
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | ||
| NCT00906334 | Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | ||
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | ||
| NCT02107235 | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | ||
| NCT02030639 | Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers | ||
| NCT01538563 | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | ||
| NCT01538537 | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | ||
| NCT01168011 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | ||
| NCT01165905 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | ||
| NCT01125891 | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors | ||
| NCT01048619 | Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome | ||
| NCT00867061 | Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) | ||
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | ||
| NCT00861328 | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | ||
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | ||
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | ||
| NCT04177498 | Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC | ||
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia | ||
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment |
